POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (latest WHO data):   U.S. 65,320    India 16,838    Brazil 71,704    Russia 10,535    The United Kingdom 6,385    France 26,788    Spain 3,021    Italy 20,840    Turkey 11,520    Germany 11,912    Columbia 3,047    Argentina 3,556    Mexico 7,793    Poland 15,253    Iran 8,404    South Africa 1,447    Ukraine 10,057    Indonesia 7,264    Peru 6,672    Czechia 15,230    The Netherlands 5,090    Canada 2,812    Chile 4,567    Romania 4,278    Iraq 5,043    Sweden 6,196    Pakistan 1,519    Philippines 2,444    Serbia 4,056    Austria 2,497    Hungary 6,278    Japan 1,180    Jordan 5,733    United Arab Emirates 2,742    Lebanon 3,369    Slovakia 2,800    Malaysia 2,063    Belarus 1,311    Bulgaria 1,154    Palestine 2,300    Greece 2,679    Kuwait 1,716    Slovenia 1,209    Moldova 1,550    Paraguay 1,341    Ethiopia 1,161    Libya 1,002    Estonia 1,417    China 20    Singapore 19    New Zealand 0    Australia 6    South Korea 398   

Low-cost blood test could be key weapon against No. 4 cancer killer in U.S.

Staff Writer |
A new, low-cost blood test may be an effective way to detect pancreatic cancer early, a research team says.

Article continues below

The nation's No. 3 cancer killer, pancreatic cancer often goes undiagnosed until it is too far along to remove.

Current screening techniques typically catch it only "after it causes pronounced symptoms, when it has advanced far enough to be lethal," said study author Kenneth Zaret, director of the University of Pennsylvania's Institute for Regenerative Medicine.

Sometimes it's found during a body scan for another health issue. But such scans are too costly for routine screening, even for people with a high risk of pancreatic cancer, he said. That includes parents, siblings or children of people who have had pancreatic cancer; those with some gene mutations; and people over 50 who suddenly develop diabetes.

"A low-cost, noninvasive test, such as we have developed, could be useful for routine screening of individuals who are at high risk for pancreatic cancer," Zaret said.

Current screening focuses on shifting levels of tell-tale blood proteins, according to the American Cancer Society. But such tests are considered unreliable, and the ACS does not recommend routine screening for those who are not known to be at high-risk.

Zaret's team set out to find new, reliable markers for early stage pancreatic cancer.

To begin, the researchers genetically "reprogrammed" late-stage cancer cells to mimic cells at the early stage of cancer. They identified several new cellular "biomarkers" triggered by the onset of disease.

Then, the team did three rounds of testing in roughly 700 blood samples. Samples were drawn from pancreatic cancer patients (at different stages of disease) and from healthy people.

Researchers were able to diagnose early stage pancreatic cancer - with 98 percent accuracy - by screening for two of the new biomarkers they identified, called THBS2 and CA19-9.

Zaret expressed confidence in the results so far. He said the screening tool would, at minimum, appear to be "useful" for testing people known to be at high risk for pancreatic cancer. He added it might lead to development of new, early stage treatments.

"It is noteworthy that the biomarker panel employs existing technology that is routinely available in diagnostic clinics around the country, facilitating the dissemination of the test, with further validation," Zaret said.

But that validation will require a much larger study to find out whether the new approach holds up as a screening tool for the general population.

What to read next

Chilean engineer develops early cancer detection system
DNA Mapping may lead to personalized cancer treatment
Doctors in South Korea successfully detect cancer cells in blood